Philips and Masimo Collaborate to Enhance Patient Monitoring Capabilities

Amsterdam, the Netherlands, and Irvine, California, U.S. – Royal Philips and Masimo, two leading companies in the healthcare technology sector, have announced a significant advancement in patient monitoring capabilities. The recent FDA clearance allows the activation of SedLine Brain Function Monitoring, Regional Oximetry (O3), and CO₂ measurements in Philips Patient Monitors – IntelliVue MX750 and MX850. This collaborative effort aims to provide clinicians with quick and informed decision-making tools, eliminating the need for additional monitoring equipment.

By integrating Masimo’s advanced measurements into Philips’ high acuity IntelliVue MX series monitors, healthcare professionals can conveniently assess and monitor blood saturation in the brain, anesthetic sedation, and patient respiratory performance from a single monitor. Additionally, the shared data between monitors enhances care providers’ ability to make decisive actions, resulting in a more holistic view of the patient. This integration not only improves patient care but also contributes to reducing the overall cost of care.

Christoph Pedain, General Manager, Hospital Patient Monitoring at Philips, expressed his excitement about the collaboration, stating, “Our work with Masimo has enabled us to forge new paths in continuous monitoring. We’re connecting data and technologies to help arm care providers with the robust information they need to make timely, informed care decisions for their patients.”

Jon Coleman, President of Worldwide OEM Sales and Global Health at Masimo, emphasized the mutual benefits of this partnership, saying, “Combining our expertise in noninvasive monitoring and signal processing technologies with Philips’ expertise in integrated patient monitoring and therapy solutions is a win-win for patients and clinicians alike.” Coleman added that they are proud to have their innovative technologies available to Philips customers and look forward to continuing the partnership to improve patient outcomes and reduce the cost of care.

Since their partnership began in 2016, Philips and Masimo have continually introduced advanced monitoring capabilities to select IntelliVue MX-series monitors. The latest announcement showcases the expansion of O3 regional oximetry capability to Philips’ high acuity MX750 and MX850 monitors, as well as the introduction of SedLine Brain Function Monitoring and CO₂ measurement capabilities. These additions further strengthen Philips’ portfolio of patient monitoring solutions, supporting clinical workflow, caregiver efficiencies, and ultimately enhancing patient care.

Readers are invited to share their thoughts on this collaboration and the future of continuous monitoring by visiting www.philips.com/masimo.

Photo: Philips